Regeneron said total revenues for Q2 2025 were $3,676 million, up 4% from $3,547 million in the prior-year quarter, GAAP diluted earnings per share were $12.81, and non-GAAP diluted earnings per share were $12.89.

1. 01

   Regeneron said total revenues for Q2 2025 were $3,676 million, up 4% from $3,547 million in the prior-year quarter, GAAP diluted earnings per share were $12.81, and non-GAAP diluted earnings per share were $12.89.

2. 02

   The company said EYLEA HD U.S. net sales for Q2 were $393 million, up 29%, and EYLEA U.S. net sales were $754 million, down 39%, with combined EYLEA HD and EYLEA U.S. net sales of $1,147 million, down 25%.

3. 03

   Regeneron said it expects regulatory approvals to be delayed for its currently pending FDA applications for EYLEA HD with PDUFA dates in August 2025, related to observations from an FDA site inspection at Catalent Indiana LLC. The company disclosed that on July 30 the FDA issued a Complete Response Letter for the BLA for odronextamab.

4. 04

   The company said it repurchased shares of common stock and recorded the cost of $1.070 billion as Treasury Stock during Q2, and as of June 30, 2025 $2.814 billion remained available for share repurchases. Regeneron said its full-year GAAP R&D guidance was updated from $5.560–$5.795 billion to $5.660–$5.790 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.